+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review

Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Karyopharm Therapeutics Inc (Karyopharm) discovers and develops novel drugs for the treatment of cancer and other diseases. The company’s core technology harnesses the inhibition of nuclear export as a mechanism to treat patients suffering from cancer. Karyopharm’s lead product, Xpovio, is being developed for the treatment of multiple myeloma, and relapsed or refractory diffuse large B-cell lymphoma. Its pipeline drug candidates include selinexor, eltanexor, and KPT-9274. Karyopharm’s drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and endometrial cancer. The company has operations in the US, Israel and Germany. Karyopharm is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc Key Recent Developments

  • May 08, 2024: Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
  • Feb 29, 2024: Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
  • Sep 01, 2023: Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors
  • May 04, 2023: Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Karyopharm Therapeutics Inc - Key Facts
  • Karyopharm Therapeutics Inc - Key Employees
  • Karyopharm Therapeutics Inc - Key Employee Biographies
  • Karyopharm Therapeutics Inc - Major Products and Services
  • Karyopharm Therapeutics Inc - History
  • Karyopharm Therapeutics Inc - Company Statement
  • Karyopharm Therapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Karyopharm Therapeutics Inc - Business Description
  • Other Break-up: License and Other Revenue
  • Performance
  • Other Break-up: Product Revenue, Net
  • Performance
  • R&D Overview
  • Karyopharm Therapeutics Inc - Corporate Strategy
  • Karyopharm Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Karyopharm Therapeutics Inc - Strengths
  • Karyopharm Therapeutics Inc - Weaknesses
  • Karyopharm Therapeutics Inc - Opportunities
  • Karyopharm Therapeutics Inc - Threats
  • Karyopharm Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Karyopharm Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 08, 2024: Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
  • Feb 29, 2024: Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
  • Sep 01, 2023: Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors
  • May 04, 2023: Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
  • Feb 15, 2023: Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
  • Feb 08, 2023: Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
  • Jan 09, 2023: Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Karyopharm Therapeutics Inc, Key Facts
  • Karyopharm Therapeutics Inc, Key Employees
  • Karyopharm Therapeutics Inc, Key Employee Biographies
  • Karyopharm Therapeutics Inc, Major Products and Services
  • Karyopharm Therapeutics Inc, History
  • Karyopharm Therapeutics Inc, Subsidiaries
  • Karyopharm Therapeutics Inc, Key Competitors
  • Karyopharm Therapeutics Inc, Ratios based on current share price
  • Karyopharm Therapeutics Inc, Annual Ratios
  • Karyopharm Therapeutics Inc, Interim Ratios
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Karyopharm Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Karyopharm Therapeutics Inc, Performance Chart (2019 - 2023)
  • Karyopharm Therapeutics Inc, Ratio Charts
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Shanghai Junshi Biosciences Co Ltd
  • Takeda Pharmaceuticals USA Inc
  • Amgen Inc
  • Stemline Therapeutics Inc
  • Kite Pharma Inc
  • Incyte Corp